On January 20, 2026, Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (NASDAQ:HIMS), engaged in notable stock transactions involving the company’s Class A Common Stock. Okupe sold 9,067 shares at a weighted average price of approximately $30.34 per share, generating gross proceeds near $275,113. The per-share prices within this transaction ranged narrowly from $30.21 to $30.44.
In conjunction with this sale, Okupe exercised options to acquire a matching total of 9,067 shares of Hims & Hers’ Class A stock. These exercised options were divided into two tranches: 7,317 shares acquired at an exercise price of $5.01 each, and a further 1,750 shares acquired at $11.53 per share, totaling an outlay of $56,835. Following completion of these transactions, Okupe holds a direct ownership of 91,617 shares and controls an additional 7,853 shares indirectly through a designated trust - the Oluyemi Okupe Separate Property Trust.
These activities were conducted under a Rule 10b5-1 trading plan established on May 21, 2025, enabling transactions to occur pursuant to predetermined terms independent of any insider information.
Separately, Hims & Hers has recently been the focus of varied analyst reviews and market developments. Morgan Stanley assigned an Equalweight rating and forecasted that revenue growth, which reached 111% year-over-year in the first quarter of 2025, would moderate to 49% by the third quarter of 2025, continuing to decelerate over 2026 and 2027.
Meanwhile, Evercore ISI initiated coverage with an In Line rating and set a price target of $33.00. The firm appreciated the reasonable valuation but highlighted possible risks. Additionally, BofA Securities revised its price target downward from $32.00 to $29.00, citing concerns about Hims & Hers hitting revenue growth expectations in 2026. The Underperform rating was reaffirmed alongside comments on weaker-than-anticipated online revenue in Q4.
Market competition has intensified following Amazon Pharmacy's announcement to distribute Novo Nordisk’s Wegovy weight-loss medication, posing potential challenges to Hims & Hers' foothold in the weight management arena.
These developments — encompassing insider stock transactions, analyst outlooks, and competitive dynamics — provide investors with a comprehensive perspective on Hims & Hers’ current positioning and the hurdles ahead.